Page 92 - 2019秋季手冊內頁-ebook測試

2010, 9(2): 450-60. (Co‐first author and Correspondent)
2. Jin‐Hwang Liu*, Chin-Cheng Liu, Chueh-Chuan Yen, Jyh-Pyng Gau, Wei‐Shu Wang, Cheng-
Hwai Tzeng. PML and TAp73 interacting at nuclear body mediate imatinib-induced p53- independent apoptosis of chronic myeloid leukemia cells. Int J Cancer 2009;125:71-7.
3. Po-Shen Ko, Yao-Chung Liu, Chiu-Mei Yeh, Jyh-Pyng Gau,Yuan-Bin Yu, Liang-Tsai Hsiao, Cheng-Hwai Tzeng, Po-Min Chen,Tzeon-Jye Chiou,Chia-Jen Liu, Jin‐Hwang Liu*. The Uniqueness of Morphological Features of Pure Erythroid Leukemia in Myeloid Neoplasm with Erythroid Predominance: A Reassessment Using Criteria Revised in the 2016 World Health Organization Classification. Plos One. 2017 Feb 14;12(2):e0172029. doi: 10.1371/journal.pone.0172029.
4. Tsai CK, Huon LK, Ou SM, Kuan AS, Yeh CM, Lee YT, Liu YC, Chen TJ, Liu JH*, Liu CJ. Risk and impact of tuberculosis in patients with multiple myeloma. Leuk Lymphoma. 2017 Nov;58(11):2598-2606.
5. Hsu YT, Tsai HJ, Chang JS, Li SS, Tang JL, Yeh SP, Hwang WL, Liu JH, Tan TD, Wang PN, Hsiao HH, Chen TY. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant. 2018 Feb 12. doi: 10.1038/s41409-018-0116-6. [Epub ahead of print]
INVENTOR OF PATENT:
1. United States Patent, Patent no.: US 8,263,398 B2, Novo promoter and viral vector containg the same. Effective since Sep 11, 2012.
2. .Patent issued by Taiwan, ROC: 中華民國專利 , Patent no. I 391486號, 新穎起動子及 包含其之病毒載體, 效期: 2013/04/01- 2029/10/19.
3. Patent issued by PRC, 中國大陸第200910260793.X號發明專利, (核准日期:102年5 月21日)事發明名稱:新颖启动子及包含其之病毒载体. Effecive since Dec 29, 2009 for 20 years.
4. Patent issued by Hong Kong, 香港第11108772.4號標準專利, A novel promoter and viral vector containing the same, Effecive since Dec 29, 2009 for 20 years.
5. 美國發明專利申請案第15/095,508號 (2017) NEW METHOD FOR TREATING A CANCER. The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expres-sion of checkpoint kinase 1 (CHK-1) is low.
93